You are here

  • Home
  • Archive
  • Volume 11, Issue 5
  • First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

 

Online download statistics by month:

Online download statistics by month: May 2023 to July 2025

AbstractFullPdf
May 202341341573
Jun 202353053583
Jul 202316616662
Aug 202320020053
Sep 202313613647
Oct 202313413528
Nov 202314714845
Dec 202317017150
Jan 20249810164
Feb 2024959640
Mar 202415415494
Apr 202411511561
May 202411511546
Jun 202411311357
Jul 202412812937
Aug 2024848237
Sep 2024606230
Oct 2024939450
Nov 202413914057
Dec 202412813160
Jan 202511711737
Feb 202520420445
Mar 202512412446
Apr 202512412457
May 202515015047
Jun 202511611741
Jul 2025110
Total405440751347